In this episode, Senior Producer and Host Martha Carlson embraces the hope that we can do something to help our closest relatives avoid metastatic breast cancer and even early-stage breast cancer. Despite living with no known inheritable mutation associated with breast cancer risk, Martha has MBC and her Mom recently died of the same disease. Now, her 20-something oldest child has discovered an additional factor that puts her at increased risk. Listen along as they discuss risk reduction and what steps have been recommended, followed by an informative interview with Dr. Sagar Sardesai of Ohio State University Comprehensive Cancer Center. He is the Co-Director of OSU High Risk Breast Clinic, along with Dr. Doreen Agnese, where they see people of all ages who are at elevated risk for breast cancer, whether due to known or unknown inheritable factors, family history, previous treatments, and more. We talk about what it means to live with high risk, the options for monitoring, when and how to begin, and why it matters. It’s another great episode from OMBCL, and we hope you learn a lot.

On today's episode, we are thrilled to discuss an important and often misunderstood area of oncology: Biosimilars and their increasing use in cancer care.

You might be curious, what exactly are biosimilars? How are they developed and approved? And most importantly, how are they transforming the lives of patients diagnosed with cancer?

We will break down these questions and more with an overview from Dr. Julie Gralow, a breast medical oncologist and chief medical officer at the American Society of Clinical Oncology.

For our Season 9 opening episode, we're learning about agnostic
treatments in cancer with Dr. Richard Schilsky of ASCO, who discusses the
TAPUR Study. You may wonder, what is TAPUR and how does it relate to agnostic
treatments? The pioneer behind the study, Dr. Schilsky, explains clinical trials for agnostic therapeutics, how you can join a TAPUR trial, and what to expect.